News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Researchers Receive Grants From National Comprehensive Cancer Network Oncology Research Program Funded Through AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) (AVEO)/Astellas Pharma Inc. (YPH.BE) Collaboration


10/15/2012 10:19:24 AM

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces funding of five new investigator-initiated studies of tivozanib, an investigational agent currently being evaluated in advanced renal cell carcinoma and other tumors. These grants were made possible through a research grant from AVEO Oncology and Astellas Pharma Inc. (Tokyo: 4503) to develop oncology research protocols and trials examining tivozanib as a single agent and in combination with other drugs in the treatment of solid tumors.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES